These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 30818144)

  • 81. The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489.
    Soung YH; Ju J; Chung J
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201253
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.
    Chen Y; Wang X; Du F; Yue J; Si Y; Zhao X; Cui L; Zhang B; Bei T; Xu B; Yuan P
    Cancer Biol Med; 2023 Mar; 20(2):155-68. PubMed ID: 36861447
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
    Kawazu M; Kojima S; Ueno T; Totoki Y; Nakamura H; Kunita A; Qu W; Yoshimura J; Soda M; Yasuda T; Hama N; Saito-Adachi M; Sato K; Kohsaka S; Sai E; Ikemura M; Yamamoto S; Ogawa T; Fukayama M; Tada K; Seto Y; Morishita S; Hazama S; Shibata T; Yamashita Y; Mano H
    PLoS Genet; 2017 Jun; 13(6):e1006853. PubMed ID: 28636652
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
    Zhang L; Wu Z; Li J; Zhu D; Yang L; Shao Y; Lin Y; Liu Z; Cao Y; Zhang G; Shang S; Zhang Y; Wang K
    JCO Precis Oncol; 2023 Jan; 7():e2200337. PubMed ID: 36652665
    [TBL] [Abstract][Full Text] [Related]  

  • 86.
    Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
    Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
    Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
    Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Somatic mutations in four novel genes contribute to homologous recombination deficiency in breast cancer: a real-world clinical tumor sequencing study.
    Huang Y; Qiu Y; Ding L; Ren S; Jiang Y; Luo J; Huang J; Yin X; Fu S; Zhao J; Hu K; Liao J
    J Pathol Clin Res; 2024 Mar; 10(2):e12367. PubMed ID: 38504382
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
    Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
    [No Abstract]   [Full Text] [Related]  

  • 90. Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
    Yndestad S; Engebrethsen C; Herencia-Ropero A; Nikolaienko O; Vintermyr OK; Lillestøl RK; Minsaas L; Leirvaag B; Iversen GT; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Aase HS; Aas T; Gudlaugsson EG; Llop-Guevara A; Serra V; Janssen EAM; Lønning PE; Knappskog S; Eikesdal HP
    JCO Precis Oncol; 2023 Sep; 7():e2300338. PubMed ID: 38039432
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    Golan T; Stossel C; Atias D; Buzhor E; Halperin S; Cohen K; Raitses-Gurevich M; Glick Y; Raskin S; Yehuda D; Feldman A; Schvimer M; Friedman E; Karni R; Wilson JM; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Gallinger S; Berger R
    Int J Cancer; 2018 Jul; 143(1):179-183. PubMed ID: 29396858
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
    Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
    Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
    Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
    Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
    [TBL] [Abstract][Full Text] [Related]  

  • 94. BRCAness: a deeper insight into basal-like breast tumors.
    De Summa S; Pinto R; Sambiasi D; Petriella D; Paradiso V; Paradiso A; Tommasi S
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii13-viii21. PubMed ID: 24131964
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    Chopra N; Tovey H; Pearson A; Cutts R; Toms C; Proszek P; Hubank M; Dowsett M; Dodson A; Daley F; Kriplani D; Gevensleben H; Davies HR; Degasperi A; Roylance R; Chan S; Tutt A; Skene A; Evans A; Bliss JM; Nik-Zainal S; Turner NC
    Nat Commun; 2020 May; 11(1):2662. PubMed ID: 32471999
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 97. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
    Min A; Kim K; Jeong K; Choi S; Kim S; Suh KJ; Lee KH; Kim S; Im SA
    Sci Rep; 2020 Jul; 10(1):12506. PubMed ID: 32719318
    [TBL] [Abstract][Full Text] [Related]  

  • 98. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
    Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy.
    Wang X; Hu N; Cui L; Si Y; Yue J; Zheng F; Kang Y; Yuan P
    Curr Cancer Drug Targets; 2022; 22(6):530-536. PubMed ID: 35156571
    [TBL] [Abstract][Full Text] [Related]  

  • 100. PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    Layman RM; Arun B
    Cancer J; 2021 Jan-Feb 01; 27(1):67-75. PubMed ID: 33475295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.